基因定义的同源小鼠卵巢癌模型用于发现联合免疫治疗
研究构建了携带人高级别浆液性输卵管卵巢癌(HGSC)基因型的小鼠模型,可在同源免疫健全宿主中成瘤。模型包括同源重组缺陷型(Trp53、Brca1、Pten、Nf1缺失联合Myc和Trp53 R172H过表达)及同源重组 proficient 型(Trp53缺失联合Ccne1、Akt2、Trp53 R172H过表达,由KRAS G12V或Brd4/Smarca4过表达驱动)。这些模型再现了人类疾病特征及基因型驱动的治疗反应,并鉴定出卵泡抑素(follistatin)驱动免疫检查点抑制剂耐药。
要点
- 构建了基因型匹配人HGSC的同源小鼠模型,可在免疫健全宿主成瘤。
- 同源重组缺陷模型通过Trp53、Brca1、Pten、Nf1缺失及Myc、Trp53 R172H过表达实现。
- 在Ccne1过表达模型中,卵泡抑素驱动免疫检查点抑制剂耐药。
核心结论
- 基因定义的同源小鼠HGSC模型可再现人类疾病并用于发现联合免疫治疗新靶点。
- 卵泡抑素被鉴定为免疫检查点抑制剂耐药的驱动因素。
研究设计与样本
- 研究构建了一系列携带人HGSC基因型的小鼠输卵管上皮细胞模型,在同源免疫健全宿主中成瘤。
- 同源重组缺陷模型:Trp53、Brca1、Pten、Nf1缺失联合Myc和Trp53 R172H过表达。
- 对照模型携带野生型Brca1。
- 同源重组 proficient 模型:Trp53缺失联合Ccne1、Akt2、Trp53 R172H过表达,由KRAS G12V或Brd4或Smarca4过表达驱动。
主要发现
- 模型形成的肿瘤再现人类疾病,包括基因型驱动的治疗反应。
- 在Ccne1过表达模型中,卵泡抑素驱动对检查点抑制剂的耐药。
临床怎么用
- 这些模型可用于鉴定HGSC中新的免疫治疗靶点及联合治疗策略。
- 卵泡抑素可能作为免疫检查点抑制剂耐药的潜在生物标志物或治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite advances in immuno-oncology, the relationship between tumor genotypes and response to immunotherapy remains poorly understood, particularly in high-grade serous tubo-ovarian carcinomas (HGSC). We developed a series of mouse models that carry genotypes of human HGSCs and grow in syngeneic immunocompetent hosts to address this gap. We transformed murine-fallopian tube epithelial cells to phenocopy homologous recombination-deficient tumors through a combined loss of Trp53, Brca1, Pten, and Nf1 and overexpression of Myc and Trp53 R172H, which was contrasted with an identical model carrying wild-type Brca1. For homologous recombination-proficient tumors, we constructed genotypes combining loss of Trp53 and overexpression of Ccne1, Akt2, and Trp53 R172H, and driven by KRAS G12V or Brd4 or Smarca4 overexpression. These lines form tumors recapitulating human disease, including genotype-driven responses to treatment, and enabled us to identify follistatin as a driver of resistance to checkpoint inhibitors. These data provide proof of concept that our models can identify new immunotherapy targets in HGSC. SIGNIFICANCE: We engineered a panel of murine fallopian tube epithelial cells bearing mutations typical of HGSC and capable of forming tumors in syngeneic immunocompetent hosts. These models recapitulate tumor microenvironments and drug responses characteristic of human disease. In a Ccne1-overexpressing model, immune-checkpoint resistance was driven by follistatin.This article is highlighted in the In This Issue feature, p. 211.
引用
- Iyer S, Zhang S, Yucel S, et al. Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy. Cancer Discov. 2020. PMID: 33158843. doi:10.1158/2159-8290.CD-20-0818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。